3-(苯基氨基甲酰基)苯甲酸 | 16776-94-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(苯基氨基甲酰基)苯甲酸
• 英文名称: 3-(phenylcarbamoyl)benzoic acid
• CAS: 16776-94-6
• 化学式: C₁₄H₁₁NO₃
• 分子量: 241.246
• InChiKey: OFHSAGBLERSCES-UHFFFAOYSA-N

物化性质

• 沸点：
  369.4±25.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(苯基氨基甲酰基)苯甲酸 在 盐酸 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 3-phenylcarbamoylbenzhydroxamic acid
  参考文献：
  名称：

  具有抗神经母细胞瘤活性的选择性组蛋白脱乙酰基酶8（HDAC8）抑制剂的基于结构的设计和生物学特性

  摘要：

  组蛋白脱乙酰基酶（HDACs）是表观遗传基因调控的重要调节剂，还可以控制非组蛋白的蛋白质底物的活性。对于HDAC 1–3和6，已经获得了许多有效的选择性抑制剂，而对于其他亚型，对选择性抑制剂及其抑制作用的了解却很少。本报告描述了取代的苯氧肟酸作为有效的和选择性的HDAC8抑制剂的发展。使用可用晶体结构的对接研究已用于该系列化合物的基于结构的优化。在这项研究中，我们研究了HDAC8在癌细胞增殖中的作用，并优化了体外和细胞培养中命中率和选择性的命中。基于结构的设计，综合，

  DOI：

  10.1021/acs.jmedchem.7b01447
• 作为产物：
  描述：

  benzyl 3-(phenylcarbamoyl)benzoate 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、400.01 kPa 条件下， 反应 5.0h， 以70%的产率得到3-(苯基氨基甲酰基)苯甲酸
  参考文献：
  名称：

  Development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors

  摘要：

  Human 5-lipoxygenase (5-LOX) is a well-validated target for anti-inflammatory therapy. Development of novel 5-LOX inhibitors with higher activities is highly demanded. In previous study, we have built a model for the active conformation of human 5-LOX, and identified naphthalen-1-yl 3,5-dinitrobenzoate (JMC-4) as a 5-LOX inhibitor by virtual screening. In the present work, 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors were developed. Twenty aryl 3,5-dinitrobenzoates, N-aryl 3,5-dinitrobenzamides and analogues were designed and synthesized. Several of them were found with significantly increased activities according to cell-free assay and human whole blood assay. The structure-activity relationship study may provide useful insights for designing effective 5-LOX inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.03.008

文献信息

• [EN] FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS FLUORÉS DE LA LYSYL OXYDASE-LIKE 2 ET UTILISATIONS DESDITS INHIBITEURS
  申请人：PHARMAKEA INC

  公开号：WO2016144703A1

  公开（公告）日：2016-09-15

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述的是一种LOXL2抑制剂化合物，制备这种化合物的方法，包含这种化合物的药物组合物和药物，以及使用这种化合物治疗与LOXL2活性相关的疾病、病症或疾病的方法。
• Ureylene phenylene anionic naphthalene-sulfonic acids, their use as complement system inhibitors in a body fluid and process for their preparation
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0008154A1

  公开（公告）日：1980-02-20

  The present invention provides novel ureylene phenylene anionic naphthalenesulfonic acids, which have complement-inhibiting properties and which may be represented by the general formula: wherein X and Y are each selected from the group consisting of -CO- and -SO2-; R and R3 are each selected from the group consisting of hydrogen, methyl and -S03A, wherein A is a pharmaceutically acceptable salt cation; R, and R4 are each selected from the group consisting of hydrogen and -COOB. wherein B is selected from the group consisting of hydrogen and a pharmaceutically acceptable salt cation; R2 and Rs are each selected from the group consisting of hydrogen and methyl; with the proviso that R. R,, R2, R3, R4 and R5 may not all be hydrogen; with the second proviso that when X and Y are both -CO- and R2 is methyl, then R, R,, R3, R. and Rs may not all be hydrogen; and with the third proviso that no phenyl moiety can contain both -SO3A and -COOB. The corresponding amine compounds of the formula below are novel intermediates for the novelureylene compounds above:

  本发明提供了具有补体抑制特性的新型脲苯基阴离子萘磺酸，其可由通式表示： 其中 X 和 Y 各自选自由 -CO- 和 -SO2- 组成的组；R 和 R3 各自选自由氢、甲基和 -S03A 组成的组，其中 A 是药学上可接受的阳离子盐；R 和 R4 各自选自由氢和 -COOB 组成的组。其中 B 选自氢和药学上可接受的盐阳离子组成的组；R2 和 Rs 各选自氢和甲基组成的组；但书中 R、R、R2、R3、R4 和 R5 不一定都是氢；第二个但书是当 X 和 Y 都是-CO-且 R2 是甲基时，则 R、R、R3、R.和 Rs 不一定都是氢；第三个但书是任何苯基都不能同时含有-SO3A 和-COOB。 下式中相应的胺化合物是上述新脲烯类化合物的新型中间体：
• Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
  申请人：PharmAkea, Inc.

  公开号：US10150732B2

  公开（公告）日：2018-12-11

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了作为 LOXL2 抑制剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 LOXL2 活性相关的病症、疾病或失调的方法。
• FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
  申请人：Pharmakea, Inc.

  公开号：EP3265456A1

  公开（公告）日：2018-01-10
• Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity
  作者：Tino Heimburg、Fiona R. Kolbinger、Patrik Zeyen、Ehab Ghazy、Daniel Herp、Karin Schmidtkunz、Jelena Melesina、Tajith Baba Shaik、Frank Erdmann、Matthias Schmidt、Christophe Romier、Dina Robaa、Olaf Witt、Ina Oehme、Manfred Jung、Wolfgang Sippl

  DOI：10.1021/acs.jmedchem.7b01447

  日期：2017.12.28

  Histone deacetylases (HDACs) are important modulators of epigenetic gene regulation and additionally control the activity of non-histone protein substrates. While for HDACs 1–3 and 6 many potent selective inhibitors have been obtained, for other subtypes much less is known on selective inhibitors and the consequences of their inhibition. The present report describes the development of substituted benzhydroxamic

  组蛋白脱乙酰基酶（HDACs）是表观遗传基因调控的重要调节剂，还可以控制非组蛋白的蛋白质底物的活性。对于HDAC 1–3和6，已经获得了许多有效的选择性抑制剂，而对于其他亚型，对选择性抑制剂及其抑制作用的了解却很少。本报告描述了取代的苯氧肟酸作为有效的和选择性的HDAC8抑制剂的发展。使用可用晶体结构的对接研究已用于该系列化合物的基于结构的优化。在这项研究中，我们研究了HDAC8在癌细胞增殖中的作用，并优化了体外和细胞培养中命中率和选择性的命中。基于结构的设计，综合，